EVGN
Evogene Ltd.
NASDAQ · Healthcare · Biotechnology · IL
$0.50
−0.85%Next report
Analyst consensus
- Next report date
- Nov 18, 2026
- EPS estimate
- -$0.27
- Revenue estimate
- $400.0K
Latest reported
- Last report date
- Aug 18, 2026
- EPS actual
- -$0.13
- EPS estimate
- -$0.27
- Revenue actual
- $347.0K
- Revenue estimate
- $320.8K
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 5
- EPS misses (12Q)
- 6
- EPS in line (12Q)
- 1
- Avg surprise (4Q)
- -56.1%
- Revenue beats (12Q)
- 7
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 18, 2026 | -$0.27 | -$0.13 | Beat 51.85% | $347.0K |
| May 29, 2026 | -$0.27 | -$0.60 | Miss -122.22% | $334.0K |
| Mar 5, 2026 | -$0.26 | -$0.61 | Miss -134.62% | $314.0K |
| Nov 20, 2025 | -$0.26 | -$0.31 | Miss -19.23% | $312.0K |
| Aug 19, 2025 | -$0.63 | -$0.62 | Beat 0.80% | $884.0K |
| May 21, 2025 | -$0.63 | -$0.38 | Beat 39.20% | $2.4M |
| Mar 6, 2025 | -$0.72 | $0.06 | Beat 108.33% | $1.6M |
| Nov 21, 2024 | -$1.01 | -$1.31 | Miss -29.70% | $1.8M |
| Aug 22, 2024 | -$0.12 | -$1.06 | Miss -783.33% | $914.0K |
| May 23, 2024 | -$0.09 | -$0.80 | Miss -788.89% | $4.2M |
| Mar 7, 2024 | -$1.40 | -$1.30 | Beat 7.14% | $578.0K |
| Nov 15, 2023 | -$1.70 | -$0.80 | Beat 52.94% | $3.8M |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 18, 2026